ストックスクリーナーアプリを入手
21.76
1.18%
-0.26
アフターアワーズ：
21.76
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Does ACADIA Pharmaceuticals Inc stock reflect fundamentals2026 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Breakout Watch: What is the target price for ACADIA Pharmaceuticals Inc stockWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock - National Today
ACAD Stock Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Neuren Pharmaceuticals advances Rett syndrome treatment with US launch of DAYBUE STIX - BioMelbourne Network
Sectors Review: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
(ACAD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock - Investing.com
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Acadia (NASDAQ: ACAD) officer sells shares to cover RSU tax obligations - Stock Titan
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome - National Today
Acadia Pharmaceuticals (ACAD) Expands Access to Rett Syndrome Tr - GuruFocus
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Bakersfield.com
User - The Chronicle-Journal
RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD.MX) Income Statement - Yahoo! Finance Canada
Advantage Alpha Capital Partners LP's ACADIA Pharmaceuticals Inc(ACAD) Holding History - GuruFocus
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharma EVP Schneyer sells $159k in stock By Investing.com - Investing.com Australia
Acadia Pharma EVP Schneyer sells $159k in stock - Investing.com UK
Acadia Pharmaceuticals exec sells $41,895 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals exec sells $41,895 in stock - Investing.com
Acadia EVP Thompson sells $73k in stock after option exercise - Investing.com
Acadia EVP Rhodes sells $82k in stock after option exercise - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock By Investing.com - Investing.com India
Acadia EVP Rhodes sells $82k in stock after option exercise By Investing.com - Investing.com South Africa
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting - Stock Titan
ACADIA Pharmaceuticals (NASDAQ: ACAD) — Vanguard reports 0 shares in amendment - Stock Titan
Acadia Pharmaceuticals stock price forecast: overbought conditions persist as ACAD closes near key resistance - Traders Union
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
ACADIA Pharmaceuticals Shares Rise After BofA Upgrade - Moomoo
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):